Niagen Bioscience authorizes $10M share repurchase program through October 2027

Niagen Bioscience, Inc.

Board authorized up to $10M in common stock repurchases over ~2 years; expires Oct 31, 2027.
Repurchases may occur in open market or private negotiations; no obligation to buy any shares.
CEO Rob Fried states company is "an excellent investment" and program is compelling use of capital.
Program may be modified, suspended, or terminated at any time at Board's discretion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.